Form 4: MindMed CEO Sells Shares for Tax Obligations
Insider Transaction Report
MindMed CEO Robert Barrow sold 25,791 common shares on December 26, 2025, to cover tax obligations from vested restricted stock units.
Summary
- Robert Barrow, Chief Executive Officer and Director of Mind Medicine (MindMed) Inc. (MNMD), reported a transaction involving the company's common shares.
- On December 26, 2025, Mr. Barrow disposed of 25,791 common shares.
- The shares were sold at a weighted average price of $13.1469 per share, with individual sales ranging from $13.02 to $13.33.
- The sale was executed to satisfy withholding tax obligations associated with the settlement of vested restricted stock units.
- This transaction was conducted pursuant to sell-to-cover elections under a Rule 10b5-1 plan, which was adopted on June 15, 2022.
- Following this transaction, Mr. Barrow directly beneficially owns 778,477 common shares of Mind Medicine (MindMed) Inc.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary 'sell-to-cover' sale for tax purposes under a pre-arranged 10b5-1 plan, rather than a discretionary sale indicating a change in management's outlook on the company.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This is a routine insider transaction, common for executives to manage tax liabilities arising from equity compensation. It does not reflect a discretionary sale based on a change in the executive's outlook on the company's prospects, but rather a pre-planned event under a Rule 10b5-1 plan.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | The transaction was conducted under a Rule 10b5-1 plan adopted on June 15, 2022. This plan allows insiders to establish pre-arranged trading programs to avoid accusations of trading on material non-public information. | 06/15/2022 | Demonstrates adherence to corporate governance best practices regarding insider trading, providing transparency and mitigating potential conflicts of interest by pre-scheduling trades. |
Stakeholder Impact
- Shareholders: Minimal impact, as this is a routine, non-discretionary sale for tax purposes and not indicative of a change in the CEO's confidence in the company. The number of shares sold represents a small fraction of the CEO's total holdings.
- Employees: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 06/15/2022 | Date Rule 10b5-1 plan was adopted by Robert Barrow. |
| 12/26/2025 | Date of the reported transaction where common shares were sold. |
| 12/29/2025 | Date the Form 4 filing was signed. |
Recommendation
holdThe transaction is a routine 'sell-to-cover' for tax obligations under a pre-established 10b5-1 plan. It does not reflect a discretionary decision by the CEO based on a change in the company's fundamentals or future prospects. Therefore, it provides no new information to warrant a change in investment recommendation, and a 'hold' stance is appropriate.
Keywords
MindMed, MNMD, Form 4, Insider Transaction, Robert Barrow, CEO, Stock Sale, Restricted Stock Units, 10b5-1 Plan, Tax Obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.